Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

A new anti-HER2 IgE antibody potentially offers new therapy options for treatment-resistant breast and ovarian cancers.

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...

The observational study measured how physicians changed treatment plans after seeing HER2DX results and how patients did on the new plans.

Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...

Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR ...

Despite better overall prognoses, slow-growing breast cancer subtypes are associated with a higher mortality risk when ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in ...

An invasive, aggressive and fast-spreading breast cancer, which is affecting younger Indian women, may just get easier to treat. Researchers at Tata Memorial have found a hidden weak spot or an ...

After being diagnosed with breast cancer in 2022, Amy Carswell had a ‘difficult experience’, but she has ‘come out the other ...